Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma

Ojo, A; Goldenberg, I; McNitt, S; Schleede, S; Casulo, C; Zent, CS; Moore, J; Soniwala, M; Aktas, MK; Sherazi, S

doi:10.1016/j.jacadv.2023.100602

Arrhythmias & electrophysiology

Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma

JACC AdvPublished 12 Sep 2023Retrospective cohort study

Read the original article ↗PubMed

Cite

Authors' conclusion

Patients undergoing lymphoma treatment, especially those with high-risk features, may benefit from AF surveillance.

Study context

Population: Patients with lymphoma and no history of atrial fibrillation (AF) (University of Rochester Medical Center Lymphoma Database)
Participants: 1,957 patients

Exposure: Bruton tyrosine kinase inhibitors (BTKi) treatment vs non-BTKi treatment vs no treatment
Outcome: Any AF episode (ICD-10 codes)

Methodological detailssingle-centre database

Single-centre database

Main finding

As reported in the abstract

New-onset AF · 5 years after treatment initiation (rates)

BTKi25%

Non-BTKi8%

No treatment4%

Multivariable

Each group vs no treatmentHazard ratio (95% CI)P value

BTKi

5.07(2.88–8.90)

P < 0.001

Non-BTKi

1.82(1.14–2.89)

P = 0.012

Observational data: associations, not effects.

Further findings

All-cause mortality after new AF

	← Lower risk ←→ Higher risk →	HR (95% CI)
New AF	0.20.5125	3.71 (2.59–5.31)
	0.20.5125Hazard ratio (log scale)

Risk factors for AF

Age ≥64 years, male sex, hypertension and lymphoma treatment were risk factors for AF

Original publication

Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma. JACC Adv. Published 12 September 2023. doi:10.1016/j.jacadv.2023.100602

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →